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Alirocumab Treatment and Achievement of Non-High-Density
Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With
Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY
Trials
Harold E. Bays, MD, FTOS, FACC, FACE, FNLA; Lawrence A. Leiter, MD, FRCPC, FACP, FACE, FAHA; Helen M. Colhoun, MD, MFPHM, FRCP(Ed);
Desmond Thompson, PhD; Laurence Bessac, MD; Robert Pordy, MD, FACP; Peter P. Toth, MD, PhD
Background-—Non-high-density lipoprotein cholesterol (non-HDL-C) and apolipoprotein (apo) B are better predictors of
atherosclerotic cardiovascular disease risk than low-density lipoprotein cholesterol alone. US and European lipid management
guidelines support non-HDL-C and apoB as targets for lipid-lowering therapy.
Methods and Results-—This analysis evaluated the efficacy of alirocumab, a proprotein convertase subtilisin/kexin type 9
inhibitor, on non-HDL-C and apoB. Data were derived from 4983 patients enrolled in 10 randomized, placebo- or ezetimibe-
controlled Phase 3 ODYSSEY trials. Primary end point for this pooled analysis was percent reduction in non-HDL-C and apoB at
Week 24; secondary end points included the percentage of patients achieving guideline-directed treatment goals (National Lipid
Association guidelines: non-HDL-C <100 or <130 mg/dL for patients at very high and high cardiovascular risk, respectively;
European Society of Cardiology/European Atherosclerosis Society guidelines: apoB <80 mg/dL for patients at very-high
cardiovascular risk). Data were grouped according to comparator, alirocumab starting dose, and concomitant statin use. Compared
with controls, alirocumab produced significantly greater reductions in non-HDL-C and apoB at Week 24 (P<0.0001), an effect
extending up to 78 weeks. More alirocumab-treated patients achieved levels of non-HDL-C <100 mg/dL and apoB <80 mg/dL
(P≤0.0001 versus control). By Week 24, >70% of alirocumab-treated patients on background statin achieved non-HDL-C <100 or
<130 mg/dL, and apoB <80 mg/dL. Safety was comparable across pooled groups and in line with previous reports.
Conclusions-—Alirocumab produced significant, sustained reductions in non-HDL-C and apoB, allowing more patients to achieve
lipid goals compared with placebo or ezetimibe and irrespective of maximally tolerated statin use. ( J Am Heart Assoc. 2017;6:
e005639. DOI: 10.1161/JAHA.117.005639.)
Key Words: alirocumab • apolipoprotein B • cholesterol-lowering • hypercholesterolemia • non-high-density lipoprotein
cholesterol • PCSK9
G uidelines for the management of dyslipidemia havetraditionally recommended reductions in the level of
low-density lipoprotein cholesterol (LDL-C) as the primary lipid
target of therapy to reduce the risk of atherosclerotic
cardiovascular disease (ASCVD). However, LDL-C has
limitations as a predictor of ASCVD risk, particularly in
patients with elevated triglyceride levels.1
Additional pro-atherogenic lipid parameters, such as non-
high-density lipoprotein cholesterol (non-HDL-C) and
apolipoprotein (apo) B, may provide important diagnostic
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information to guide the assessment and management of
dyslipidemia and ASCVD risk.2 Current US National Lipid
Association recommendations and European Society of
Cardiology/European Atherosclerosis Society guidelines
have recognized the importance of these lipid parameters.
The National Lipid Association recommends non-HDL-C as a
co-primary therapy target alongside LDL-C, and apoB as a
secondary target, whereas European guidelines recommend
both non-HDL-C and apoB as secondary targets.3,4 Although
the 2013 American College of Cardiology/American Heart
Association guidelines do not specify non-HDL-C treatment
thresholds,5 recent recommendations from the 2016 Amer-
ican College of Cardiology Consensus Decision Pathway on
the role of nonstatin therapies for LDL-C-lowering have
introduced non-HDL-C thresholds in certain high-risk patient
groups.6
Alirocumab is a monoclonal proprotein convertase subtil-
isin/kexin type 9 inhibitor that helps prevent LDL receptor
degradation, thus increasing clearance of LDL-C and decreas-
ing LDL-C blood levels. Alirocumab was evaluated in the
ODYSSEY global Phase 3 clinical trial program comprising a
comprehensive set of clinical studies in various patient
populations. Individual studies7–14 and a pooled analysis of
8 studies in patients receiving background statin therapy15
have shown that alirocumab produces significant reductions
in LDL-C compared with placebo or ezetimibe in patients at
high cardiovascular risk.
The data for this analysis included 10 completed ODYSSEY
studies in a broad range of patients with hypercholes-
terolemia: 8 studies including alirocumab administered to
patients treated with background statin, the majority of whom
received maximally tolerated statin, or other lipid-lowering
therapies, and 2 studies involving alirocumab administered to
patients without background statin. The main aim of the
analysis was to investigate the effect of alirocumab on levels
of non-HDL-C and apoB.
Methods
Study Designs and Participants
In this analysis, data were pooled from 10 Phase 3 trials in the
ODYSSEY program, involving 4983 patients with hypercholes-
terolemia. Detailed methods for each of the 10 studies were
previously published elsewhere.7–14
In 8 trials (pools 1, 3, and 4; total n=2535 patients), the
alirocumab starting dose was 75 mg every 2 weeks (Q2W). If
pre-defined ASCVD risk-based LDL-C goals were not achieved
at Week 8, the alirocumab dose was increased in a blinded
manner to 150 mg Q2W at Week 12.7–12 The alirocumab dose
in these pooled groups is referred to herein as alirocumab
75/150 mg. In 2 trials (pool 2; total n=2448 patients),
patients received alirocumab 150 mg Q2W from the
outset.13,14
As described above, trials were pooled into 1 of 4 groups:
(1) alirocumab 75/150 mg Q2W versus placebo, on back-
ground statins (COMBO I, FH I, and FH II)8,10; (2) alirocumab
150 mg Q2W versus placebo, on background statins (LONG
TERM and HIGH FH)13,14; (3) alirocumab 75/150 mg Q2W
versus ezetimibe 10 mgdaily, on background statins (COMBO II,
OPTIONS I, and OPTIONS II)7–9; and (4) alirocumab 75/150 mg
Q2W versus ezetimibe 10 mg daily, without background statins
(ALTERNATIVE and MONO)11,12 (Table S1).
Trial length ranged from 24 to 104 weeks. Efficacy
analyses within each pool were performed to the time point
for which data were available for all trials in that pool. For
safety analyses, treatment-emergent adverse events (TEAEs)
were defined as events occurring from the first dose of
study treatment and up to 70 days after the last dose. All
subcutaneous injections (alirocumab 75, 150 mg, or placebo)
used a 1 mL injection volume. Patients provided written
informed consent before their participation. The trial proto-
cols were reviewed and approved by institutional review
boards and independent ethics committees.
The primary efficacy end point for each of these trials was
the percent change in calculated LDL-C levels from baseline
to Week 24. Secondary end points included percent change in
LDL-C at Week 12 and percent change from baseline in
non-HDL-C, apoB, HDL-C, and triglyceride levels. Given their
importance as highlighted in recent guidelines,3,4 the present
analysis focuses on the reduction of non-HDL-C and apoB. As
well as evaluating percent change from baseline, an additional
end point was the percentage of patients achieving levels of
these lipoproteins corresponding to guideline-directed treat-
ment goals (non-HDL-C <100 or <130 mg/dL for patients at
Clinical Perspective
What Is New?
• Non-high-density lipoprotein cholesterol (non-HDL-C) and
apolipoprotein B (apoB) are specified as treatment targets
by some international lipid guidelines.
• Alirocumab produced significant, sustained reductions in
non-HDL-C and apoB, allowing more patients to achieve lipid
goals.
What Are the Clinical Implications?
• Non-HDL-C and apoB are better predictors of atheroscle-
rotic cardiovascular disease risk than calculated low-density
lipoprotein cholesterol alone.
• Alirocumab effectively reduces non-HDL-C and apoB levels,
allowing for better achievement of non-HDL-C and apoB
levels corresponding to guideline treatment goals.
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very-high and high cardiovascular risk, respectively; apoB
<80 mg/dL for patients at very-high cardiovascular risk, and
<100 mg/dL for those at high risk).3,4
The definition of cardiovascular risk in the Phase 3 studies
included in this analysis varied by study. Detailed definitions
can be found within Data S1. Given that the specified
non-HDL-C goals are defined in guidelines according to the
estimated degree of ASCVD risk for a given individual, our
analysis of non-HDL-C goal attainment was performed for the
entire population regardless of individual risk as well as
stratification by very-high and high cardiovascular risk (the
vast majority of patients in the present analysis were at very-
high or high cardiovascular risk). Analysis of apoB goal
attainment was performed for the entire population regardless
of individual risk.
Statistical analyses were based on intention-to-treat (ITT)
principles (including all data regardless of adherence to
treatment) and the on-treatment (modified ITT) population.
The modified ITT population was defined as all randomized
and treated patients with a baseline non-HDL-C value and with
on-treatment non-HDL-C values during at least 1 of the
planned postbaseline time points. The on-treatment window
was defined as the period up to 21 days after last injection.
Patients who discontinued the study drug were required to
return for further clinic visits and assessments until the
scheduled final visits. Patients with missing data were
accounted for using a mixed effect model with repeated
measures. The model included fixed categorical effects of
treatment group, study, randomization strata as per interac-
tive voice system, time point, treatment-by-time point inter-
action, study-by-time point interaction, and strata-by-time
point interaction, as well as the continuous fixed covariates of
baseline lipid value and baseline lipid value-by-time point
interaction.
For analysis of safety, data were pooled into 2 groups
according to the comparator in the individual trials, compris-
ing (1) 5 placebo-controlled trials; and (2) 5 ezetimibe-
controlled trials.
Results
Participants and Baseline Characteristics
A total of 4983 patients with inadequately managed hyper-
cholesterolemia were randomized across the 10 trials.
Baseline characteristics for the pool of patients analyzed
here were reported previously16 and were generally similar
between alirocumab and control patients within each pooled
group (Table S1).
Pool 1 included the COMBO I study, which evaluated
patients at high risk of ASCVD, and the FH I and FH II studies,
which evaluated patients with heterozygous familial
hypercholesterolemia (HeFH). This pool thus included a higher
proportion of patients receiving additional nonstatin lipid-
lowering therapies and a higher proportion with familial
hypercholesterolemia compared with the other pooled groups
(Table S1).
Baseline mean LDL-C, non-HDL-C, and apoB levels
exceeded National Lipid Association and European Society
of Cardiology/European Atherosclerosis Society recom-
mended goals for high-risk hypercholesterolemia patients
(100, 130, and 100 mg/dL, respectively) in all pooled
groups. Of note, mean baseline levels for these lipid
parameters were considerably higher in the group not
receiving statin therapy (pool 4) compared with those on
statins (pools 1–3; Table S1). Median fasting triglyceride
levels at baseline ranged from 111.0 to 147.5 mg/dL
across all pooled groups.
Alirocumab dose was increased from 75 mg Q2W to
150 mg Q2W at Week 12 in 34.5% of patients in pool 1
(placebo-controlled, receiving background statins), 17.7% of
patients in pool 3 (ezetimibe-controlled, receiving back-
ground statins), and 43.9% of patients in pool 4 (ezetimibe-
controlled, no background statins). All alirocumab-treated
patients in pool 2 received alirocumab 150 mg Q2W from
the outset.
Efficacy
Changes in lipid parameters across pooled groups
The baseline levels of each lipid parameter for each of the
pools are given in Table S1. Both alirocumab and ezetimibe
reduced non-HDL-C and apoB levels from baseline. Patients
allocated to placebo (ie, receiving background statin treat-
ment with or without other lipid-lowering therapy only)
experienced mild increases in these lipid parameters (Fig-
ure 1). In all 4 pools, alirocumab produced superior reduc-
tions in non-HDL-C and apoB at 12 and 24 weeks compared
with placebo or ezetimibe, irrespective of alirocumab dose or
background statin therapy (P<0.0001; Figure 1; Table S2).
The benefit of alirocumab was apparent from the first lipid
measurement (Week 4 for non-HDL-C; Week 12 for apoB) and
was sustained throughout the trial periods for both lipid
parameters in both the modified ITT (Figure 1) and ITT
(Figure S1) population.
Data on other lipid parameters (calculated LDL-C, HDL-C,
and fasting triglyceride) from pools 1 to 3 (patients receiving
background statins) were reported previously.15 Briefly,
treatment with alirocumab 75/150 mg Q2W or 150 mg Q2W
added to statins resulted in significantly reduced LDL-C levels
at Week 24 compared with both placebo and ezetimibe in all
patient pools (P<0.0001; Table S2). In pool 4, in which
patients did not receive statins, LDL-C was significantly
DOI: 10.1161/JAHA.117.005639 Journal of the American Heart Association 3
























Figure 1. Change in non-HDL-C and apoB levels over time (on-treatment [mITT] population). A, Non-
HDL-C. B, ApoB. The percent values represent the percent change from baseline at each time point.
*P<0.0001 vs control group. ApoB indicates apolipoproteinB; LS, least squares; mITT, modified
intention-to-treat; non-HDL-C, non-high-density lipoprotein cholesterol; Q2W, every 2 weeks;
SE, standard error.
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Figure 2. Percent of patients achieving non-HDL-C levels of <100 mg/dL during the studies,
overall and by cardiovascular risk (on-treatment [mITT] population). A, All patients (regardless of
cardiovascular risk). B, Patients with very-high cardiovascular risk. C, Patients with high
cardiovascular risk. *P<0.0001 vs control group at all time points in all study pools and patient
categories, except for pool 3 and pool 4 of the “high cardiovascular risk” category where
†P=0.0030, ‡P=0.0008, §P=0.0159, and ‖P=0.0220. mITT, modified intention-to-treat; non-HDL-
C, non-high-density lipoprotein cholesterol; Q2W, every 2 weeks.
DOI: 10.1161/JAHA.117.005639 Journal of the American Heart Association 5






















reduced in the alirocumab 75/150 mg Q2W group versus
ezetimibe (P<0.0001; Table S2). Alirocumab also produced a
significant increase in HDL-C and decrease in fasting triglyc-
eride compared with placebo at Week 24 (P<0.0001;
Table S2).
Combined data from all patients in all 10 trials showed
that average LDL-C, non-HDL-C, and apoB levels were highly
correlated with one another throughout the treatment period
(Pearson correlation coefficients ≥0.922 for the 3
pairwise comparisons comparing LDL-C with either non-
HDL-C or apoB and comparing non-HDL-C with apoB; all
P<0.0001).
Achievement of non-HDL-C and apoB levels
corresponding to treatment goals
At 12 and 24 weeks, in all patients pooled regardless of
cardiovascular risk categorization, alirocumab allowed a
significantly higher percent of patients to achieve levels of
non-HDL-C <100 mg/dL, non-HDL-C <130 mg/dL (except
for pool 3 at Week 12), and apoB <80 mg/dL compared
with placebo or ezetimibe (P≤0.0001; Figures 2A, 3A,
and 4).
Data for each of the 4 individual pools are described as
follows.
Pool 1: patients receiving alirocumab 75/150 mg Q2W
or placebo with background statins (COMBO I, FH I,
and FH II). At Week 12, before the potential protocol-directed
alirocumab dose increase, alirocumab 75 mg Q2W allowed
63.5%, 81.5%, and 72.4% of patients to achieve levels of
non-HDL-C <100 mg/dL, non-HDL-C <130 mg/dL, and apoB
<80 mg/dL, respectively, in all patients pooled regardless of
cardiovascular risk categorization (Figures 2A, 3A, and 4). By
Week 24, following the potential alirocumab dose increase to
150 mg Q2W at Week 12, the percent of patients achieving
these levels rose to 72.9%, 88.0%, and 82.0%, respectively. In
contrast, 7.6%, 33.7%, and 18.3% of patients in the placebo
group achieved non-HDL-C <100 mg/dL, non-HDL-C
<130 mg/dL, and apoB <80 mg/dL levels, respectively, at
Week 24 (P<0.0001 versus control). When stratified by
cardiovascular risk, attainment of specified non-HDL-C goals
with alirocumab 75/150 mg Q2W versus placebo in patients
with very-high or high cardiovascular risk were in keeping with
those observed in the whole population (P<0.0001 versus
placebo at all time points; Figures 2B, 2C, 3B, and 3C).
Pool 2: patients receiving alirocumab 150 mg Q2W or
placebo with background statins (LONG TERM and
HIGH FH). The mean percent reductions at 24 weeks in
Figure 2. Continued.
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Figure 3. Percent of patients achieving non-HDL-C levels of <130 mg/dL during the studies,
overall and by cardiovascular risk (on-treatment [mITT] population). A, All patients (regardless of
cardiovascular risk). B, Patients with very-high cardiovascular risk. C, Patients with high
cardiovascular risk. *P<0.0001 vs control group at all time points in all study pools and patient
categories, except for pool 4 of the “high cardiovascular risk” category where †P=0.0049 and
‡P=0.0018. mITT, modified intention-to-treat; non-HDL-C, non-high-density lipoprotein choles-
terol; Q2W, every 2 weeks.
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non-HDL-C and apoB levels with alirocumab 150 mg Q2W
were numerically greater than the corresponding reductions
with alirocumab 75/150 mg Q2W observed in other groups
(Table S2). In all patients (ie, regardless of cardiovascular risk)
alirocumab 150 mg Q2W allowed 82.8% of patients to achieve
non-HDL-C <100 mg/dL, with 91.8% achieving non-HDL-C
<130 mg/dL and 88.8% achieving apoB <80 mg/dL at
Week 12 (Figures 2A, 3A, and 4) compared with 7.9%,
36.3%, and 22.6% of patients who received placebo
(P<0.0001 versus control). Similar results were obtained
when the specified non-HDL-C goal attainments were strat-
ified by cardiovascular risks (P<0.0001 versus placebo at all
time points; Figures 2B, 2C, 3B, and 3C).
Pool 3: patients receiving alirocumab 75/150 mg Q2W
or ezetimibe with background statins (COMBO II,
OPTIONS I, and OPTIONS II). Alirocumab allowed 76.8%
of all patients (pooled regardless of cardiovascular risk) to
achieve non-HDL-C <100 mg/dL at Week 12, rising slightly to
79.1% at Week 24 after the protocol-directed dose increase
(Figure 2A). Corresponding values were 89.5% (Week 12) and
90.6% (Week 24) for non-HDL-C <130 mg/dL (Figure 3A), and
83.9% (Week 12) and 85.6% (Week 24) for apoB <80 mg/dL
(Figure 4). For each time point, alirocumab allowed a
significantly greater proportion of patients to achieve each
of the specified levels than ezetimibe (P≤0.0001), except at
Week 12 (before the potential protocol-directed alirocumab
dose increase) for non-HDL-C <130 mg/dL where no signif-
icant difference between alirocumab and ezetimibe was found
(P=0.1222; Figure 3A). In patients with very-high or high
cardiovascular risk, achievement of specified non-HDL-C
goals were generally higher with alirocumab 75/150 mg
Q2W versus ezetimibe at all time points (P≤0.0030; Fig-
ures 2B, 2C, and 3B), except for non-HDL-C <130 mg/dL in
patients with high cardiovascular risk where no significant
differences between alirocumab and ezetimibe (Figure 3C)
were found.
Pool 4: patients receiving alirocumab 75/150 mg Q2W
or ezetimibe without background statin (ALTERNATIVE
and MONO). The mean percent reductions in non-HDL-C and
apoB levels at Week 24 were similar in this group compared
with other pools receiving the same alirocumab dose regimen
(75/150 mg Q2W; Table S2). However, patients in this pool
who were not receiving background statin therapy had higher
baseline lipid levels than patients in the pools with back-
ground statin (Table S1). Therefore, achievement of the
specified lipid levels was less robust in this group (Figures 2A,
Figure 3. Continued.
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3A, and 4). Nevertheless, alirocumab allowed significantly
more patients (regardless of cardiovascular risk) to achieve
the specified non-HDL-C and apoB levels compared with
ezetimibe (P<0.0001; Figures 2A, 3A, and 4). Similar results
were reported with alirocumab 75/150 mg Q2W in patients
with very-high or high cardiovascular risk for specified non-
HDL-C goals (P≤0.0220 versus ezetimibe; Figures 2B, 2C, 3B,
and 3C). Corresponding results for all goal achievement data
analyzed using the ITT population (Figures S2 through S4)
were generally similar to the aforementioned results analyzed
using the on-treatment (modified ITT) population.
Safety
Safety data for alirocumab across 14 Phase 2 and Phase 3
studies were previously reported,17,18 as were data from the
10 Phase 3 ODYSSEY studies included in the present
analysis.16,18 In the 10 Phase 3 studies evaluating Q2W
doses of alirocumab, the overall rates of TEAEs, serious
TEAEs, and discontinuations because of TEAEs were similar
for alirocumab versus control (Table S3). More patients
experienced injection-site reactions in the alirocumab group
compared with placebo (placebo-controlled studies:
alirocumab 7.2% versus 5.3% for placebo; ezetimibe-con-
trolled studies: alirocumab 2.9% versus 2.1% for ezetimibe;
Table S3).
Discussion
Non-HDL-C provides a measure of the cholesterol content of
all pro-atherogenic particles including LDL-C, very low-density
lipoprotein cholesterol, intermediate-density lipoprotein
cholesterol, remnant lipoproteins, and lipoprotein (a). One
molecule of apoB resides on each atherogenic lipoprotein.19
Therefore, in current US National Lipid Association recom-
mendations and European guidelines, both non-HDL-C and
apoB are considered important lipid treatment targets along-
side LDL-C.3,4
This analysis examined the effects of alirocumab on non-
HDL-C and apoB from 10 ODYSSEY Phase 3 studies including
4983 patients with hypercholesterolemia, pooled into 4
groups according to dose of alirocumab, use of background
statin therapy, and study control (placebo or ezetimibe).
Alirocumab produced robust and sustainable reductions in
non-HDL-C and apoB levels, as well as in LDL-C (the primary
endpoint of the studies), and average non-HDL-C and apoB
Figure 4. Percent of patients achieving apoB levels <80 mg/dL during the studies (mITT population).
*P<0.0001 vs control group at all time points and in all study pools. ApoB indicates apolipoprotein B; mITT,
modified intention-to-treat; Q2W, every 2 weeks.
DOI: 10.1161/JAHA.117.005639 Journal of the American Heart Association 9






















levels highly correlated with average LDL-C throughout the
treatment period. Compared with ezetimibe, treatment with
alirocumab more than doubled the least-squares mean
reduction in non-HDL-C and apoB levels. Substantial reduc-
tions were irrespective of concomitant statin therapy and
alirocumab dose regimen (75/150 mg Q2W or 150 mg Q2W).
Moreover, the effect of alirocumab was evident upon the first
assessment from 4 weeks, and was sustained throughout the
studies.
In addition, alirocumab allowed a high percentage of
patients to achieve non-HDL-C and apoB levels that corre-
spond to guideline-directed goals, which were sustained
throughout the studies. For example, compared with statins
alone (ie, in patients receiving placebo), alirocumab allowed a
more than 2-fold higher achievement of non-HDL-C levels of
<130 mg/dL and an almost 10-fold higher achievement of
the more stringent non-HDL-C target of <100 mg/dL at
Week 24. Moreover, in the absence of background statins,
alirocumab produced an almost 3-fold increase in the percent
of patients achieving non-HDL-C <130 mg/dL and an almost
6-fold increase in the percent achieving <100 mg/dL com-
pared with ezetimibe. With concomitant statin therapy,
alirocumab also allowed a significantly greater percentage of
patients to achieve the specified non-HDL-C levels than
ezetimibe. These were consistent overall with the results from
analysis where patients were grouped according to cardio-
vascular risk categories. Results from the present analysis are
in general agreement with achievement of LDL-C goals in a
previous analysis of 8 ODYSSEY studies in patients receiving
concomitant statin (corresponding to pools 1–3 in the current
analysis).9 In that analysis, LDL-C goal attainment was
investigated in patients grouped according to whether the
patient was at very high (LDL-C goal <70 mg/dL) or high risk
(goal <100 mg/dL) and overall 75.2–79.0% of patients
achieved these risk-based LDL-C goals.15
LDL-C in isolation may be an inadequate measure of total
ASCVD risk, as it fails to account for cholesterol carried by
other lipoproteins, such as triglyceride-rich lipoproteins. When
triglyceride levels are high, the levels of remnant atherogenic
lipoproteins are also elevated; in these circumstances, the
risk predicted by LDL-C alone is underestimated.1 In addition,
discordance between LDL-C, non-HDL-C, and apoB levels may
exist in a significant proportion of patients with dyslipidemia,
including those with metabolic syndrome, type 2 diabetes
mellitus, and obesity.20–22 For example, the Very Large
Database of Lipids 2 study showed that, among patients
achieving an LDL-C goal of ≤70 mg/dL, 15% may still have a
non-HDL-C level ≥100 mg/dL, increasing to 22% among
patients with high triglyceride levels (150–199 mg/dL).22
Such discordance means that residual ASCVD risk may be
overlooked with LDL-C-centric treatment.1 A number of
studies have demonstrated that non-HDL-C and apoB are
superior markers of ASCVD risk compared with LDL-C
alone.19,23–29 Indeed, some studies suggest that apoB levels
may have the strongest association with risk.23,24,26
Because most ASCVD outcomes trials have utilized LDL-C
as the primary lipid outcome parameter, the conclusions of
the current analysis are limited by the lack of studies
demonstrating the correlation of non-HDL-C or apoB levels as
a primary endpoint with ASCVD risk. Nevertheless, a meta-
analysis of ASCVD outcomes trials has supported the
association between reduced non-HDL-C and apoB levels
with reduced ASCVD events.30 Moreover, the randomized,
double-blind Helsinki Heart study, one of the few ASCVD
outcomes studies that evaluated non-HDL-C as the primary
lipid outcome, demonstrated an association between reduc-
tion in non-HDL-C levels and cardiovascular events.31 Fur-
thermore, a recently published post-hoc analysis from the 10
ODYSSEY trials used in the present study showed that
reductions in non-HDL-C and apoB were associated with
improved cardiovascular outcomes, regardless of the treat-
ment received during the trials.32
At the time of writing, the correlation between the lipid
effects of alirocumab and ASCVD events are unproven.
However, the ongoing ODYSSEY OUTCOMES trial
(NCT01663402) is evaluating the potential benefits of
alirocumab in reducing major cardiovascular events in patients
with acute coronary syndrome within 1 year who have not
achieved lipid management goals with intense statin therapy.
Conclusion
Non-HDL-C and apoB are useful in assessment of ASCVD risk,
and are specified as treatment targets by international lipid
guidelines. Data from this analysis of 4983 patients derived
from 4 pooled groups support the role of alirocumab in
effectively reducing levels of non-HDL-C, and apoB levels, as
well as allowing substantially better achievement of non-HDL-
C and apoB levels that correspond to guideline-directed goals
compared with placebo or ezetimibe.
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Data S1.  
Supplemental Methods 
Definition of cardiovascular risk in the Phase 3 studies included in this analysis 
The definition of cardiovascular risk and corresponding LDL-C targets in the Phase 3 
studies included in this analysis were based on US and EU guidelines in effect at the 
time of clinical development plan finalization of each studies with focus on coronary 
heart disease (CHD) and CHD risk equivalents. In FH I, FH II, HIGH FH, OPTIONS I, 
and OPTIONS II, patients with CHD (including acute or silent myocardial infarction, 
unstable angina, coronary revascularization procedure, or other clinically significant 
CHD) or CHD risk equivalent (including peripheral arterial disease [PAD], ischemic 
stroke, moderate chronic kidney disease, and known history of diabetes mellitus and 
≥2 additional risk factors) were categorized as having very-high cardiovascular risk; 
all other patients were included in the “high cardiovascular risk” category.  
In LONG TERM, heterozygous familial hypercholesterolemia (HeFH) patients with 
CHD or CHD risk equivalents (as defined above) and non-familial 
hypercholesterolemia patients were included in the “very-high cardiovascular risk” 
category (as defined above); all other patients were included in the “high 
cardiovascular risk” category (as defined above). All patients from COMBO I and 
COMBO II were assigned to the “very-high cardiovascular risk” category (as defined 
above), whereas patients from MONO were assigned to the “moderate 
cardiovascular risk” category defined as a 10 year risk Systematic Coronary Risk 
Estimation (SCORE) of ≥1% and <5%.  
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In ALTERNATIVE, very-high cardiovascular risk was defined as any documented 
history of CHD (defined above), ischemic stroke, PAD, transient ischemic attack, 
abdominal aortic aneurysm, carotid artery occlusion >50% without symptoms, carotid 
endarterectomy or carotid artery stent procedure, renal artery stenosis, renal stent 
procedure, or diabetes with target organ damages. Furthermore, in ALTERNATIVE, 
high cardiovascular risk was defined as a calculated 10-year fatal cardiovascular 
disease risk SCORE of ≥5%, moderate chronic kidney disease, HeFH with no history 
of CHD or CHD risk equivalent, and diabetes without target organ damages. 
Moderate cardiovascular disease was defined as a above. 
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Table S1. Overview of studies included in the pooled analysis and baseline characteristics (n=4983 patients with 
hypercholesterolemia) 
 Pool 1 (3 studies) Pool 2 (2 studies) Pool 3 (3 studies) Pool 4 (2 studies) 
Studies 
1. COMBO I (NCT01644175) 
• 52 weeks* 
• Alirocumab, n=209 
• Placebo, n=107 
2. FH I (NCT01623115) 
• 78 weeks* 
• Alirocumab, n=323 
• Placebo, n=163 
3. FH II (NCT01709500) 
• 78 weeks* 
• Alirocumab, n=167 
• Placebo, n=82 
1. LONG TERM 
(NCT01507831) 
• 78 weeks* 
• Alirocumab, n=1553 
• Placebo, n=788 
2. HIGH FH (NCT01617655) 
• 78 weeks* 
• Alirocumab, n=72 
• Placebo, n=35 
 




• Alirocumab, n=479 
• Ezetimibe, n=241 




• Alirocumab, n=104 
• Ezetimibe, n=102 




• Alirocumab, n=103 
• Ezetimibe, n=101 
1. ALTERNATIVE 
(NCT01709513) 
• 24 weeks 
• Alirocumab, n=126 
• Ezetimibe, n=125 
2. MONO (NCT01644474) 
• 24 weeks 
• Alirocumab, n=52 
• Ezetimibe, n=51 
 
Alirocumab dose 75/150 mg Q2W
§
 150 mg Q2W 75/150 mg Q2W
§





 Concomitant statin ± other 
LLT 
Concomitant statin ± other LLT 
Concomitant statin ± other 
LLT 
No concomitant statin 
Baseline characteristics  
Value is mean (SD) 

















Age, years 55.6 (12.9) 55.5 (12.5) 60.0 (10.8) 60.2 (10.6) 61.6 (9.7) 62.3 (9.7) 63.1 (8.1) 61.9 (9.1) 
Male, n (%) 397 (56.8) 216 (61.4) 1018 (62.6) 496 (60.3) 483 (70.4) 294 (66.2) 98 (55.1) 94 (53.4) 
Race, white, n (%) 634 (90.7) 312 (88.6) 1505 (92.6) 760 (92.3) 582 (84.8) 385 (86.7) 163 (91.6) 163 (92.6) 
BMI, kg/m
2
  30.0 (5.5) 30.1 (6.0) 30.1 (5.7) 30.5 (5.4) 30.3 (5.9) 30.7 (5.6) 29.7 (6.4) 28.4 (5.5) 
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CV risk per protocol, n (%)
#
         
High 261 (37.3) 128 (36.4) 174 (10.7) 72 (8.7) 85 (12.4) 73 (16.4) 29 (16.3) 47 (26.7) 
Very-high 438 (62.7) 224 (63.6) 1451 (89.3) 751 (91.3) 601 (87.6) 371 (83.6) 73 (41.0) 62 (35.2) 
HeFH, n (%) 490 (70.1) 245 (69.6) 348 (21.4) 174 (21.1) 26 (3.8) 18 (4.1) 14 (7.9) 25 (14.2) 
Patients on statin, n (%) 697 (99.7) 352 (100.0) 1624 (99.9) 822 (99.9) 685 (99.9) 444 (100.0) 3 (1.7) 10 (5.7) 
Patients on LLTs other than 
statin, n (%) 
395 (56.5) 217 (61.6) 487 (30.0) 244 (29.6) 74 (10.8) 54 (12.2) 51 (28.7) 66 (37.5) 
Non-HDL-C, mg/dL 155.5 (50.0) 155.8 (48.4) 155.8 (49.4) 155.4 (48.6) 139.3 (39.7) 135.4 (41.8) 211.7 (75.1) 210.8 (77.4) 
ApoB, mg/dL 106.1 (29.3) 105.6 (27.8) 103.5 (28.9) 103.3 (28.8) 94.3 (23.0) 92.3 (23.5) 131.0 (38.7) 128.6 (36.6) 
LDL-C, calculated, mg/dL 129.0 (47.3) 130.3 (45.4) 125.9 (45.9) 125.3 (44.5) 109.4 (35.6) 105.0 (36.2) 176.5 (66.8) 177.4 (66.0) 
HDL-C, mg/dL 50.5 (15.4) 49.7 (14.4) 49.8 (12.3) 49.8 (12.4) 48.0 (13.2) 48.3 (13.1) 50.5 (15.7) 53.3 (16.3) 


















Efficacy data were pooled according to study design. 
*Concomitant statin at maximally tolerated doses (defined as atorvastatin 40–80 mg, rosuvastatin 20–40 mg, or simvastatin 80 mg; lower doses were allowed with an 
investigator-approved reason).  
†No concomitant non-statin LLT allowed in COMBO II.  
‡Concomitant statin and doses in OPTIONS I were atorvastatin 20 or 40 mg, and rosuvastatin 10 or 20 mg in OPTIONS II. Concomitant treatment with other statins, ezetimibe, 
fibrates (other than fenofibrate), and red yeast rice products was prohibited. 
§75/150 mg Q2W indicates starting dose of 75 mg Q2W increasing to 150 mg Q2W at Week 12, if pre-specified LDL-C goal was not met at Week 8.  







    
  6 
‖Concomitant non-statin LLT (excluding ezetimibe) allowed in ALTERNATIVE; no concomitant LLT allowed in MONO.  
#Excludes patients with moderate CV risk from the ALTERNATIVE and MONO pools (71 and 65 patients for alirocumab and ezetimibe, respectively). 
Apo, apolipoprotein; BMI, body mass index; CV, cardiovascular; HeFH, heterozygous familial hypercholesterolemia; ITT, intention-to-treat; LDL-C, low-density lipoprotein 
cholesterol; LLT, lipid-lowering therapy; non-HDL-C, non-high-density lipoprotein cholesterol; Q1, 25th percentile; Q2W, every 2 weeks; Q3, 75th percentile; SD, standard 
deviation; TG, triglyceride. 
n = number of patients in ITT population. 
For a more detailed report of the baseline characteristics of the patients included in the pooled analysis, please see 1,2 (http://dx.doi.org/10.1016/j.ijcard.2016.08.273, 
http://dx.doi.org/10.1016/j.amjcard.2016.09.010) 
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Table S2. Change from baseline in lipid parameters at Week 24 (ITT population) 
 Pool 1:  
alirocumab 75/150 mg Q2W  
(on background statins)  
COMBO I, FH I & II 
Pool 2:  
alirocumab 150 mg Q2W 
(on background statins)  
LONG TERM, HIGH FH 
Pool 3: 
alirocumab 75/150 mg Q2W 
(on background statins) 
COMBO II, OPTIONS I & II 
Pool 4:  
alirocumab 75/150 mg Q2W 
(without statins) 
ALTERNATIVE, MONO 
Value (LS mean % [SE] 


















Calculated LDL-C  –48.6 (1.0) 4.2 (1.5) –60.4 (0.7) 0.5 (1.0) –48.9 (1.4) –19.3 (1.7) –45.6 (1.8) –14.8 (1.8) 
LS mean difference vs 
comparator (95% CI) 
–52.7 (–56.3 to –49.2) –60.9 (–63.3 to –58.5) –29.6 (–33.8 to –25.3) –30.9 (–35.9 to –25.9) 
P-value vs comparator <0.0001 <0.0001 <0.0001 <0.0001 
Non-HDL-C –41.7 (1.0) 4.7 (1.3) –51.1 (0.6) 0.4 (0.9) –41.1 (1.1) –17.8 (1.4) –40.4 (1.5) –14.7 (1.5) 
LS mean difference vs 
comparator (95% CI) 
–46.4 (–49.6 to –43.2) –51.6 (–53.7 to –49.5) –23.3 (–26.8 to –19.9) –25.7 (–29.8 to –21.6) 
P-value vs comparator <0.0001 <0.0001 <0.0001 <0.0001 
ApoB –40.2 (0.8) 1.0 (1.1) –52.2 (0.7) 0.7 (0.9) –38.6 (1.0) –15.9 (1.2) –36.5 (1.4) –11.2 (1.4) 
LS mean difference vs 
comparator (95% CI) 
–41.3 (–44.0 to –38.6) –52.9 (–55.2 to –50.7) –22.7 (–25.8 to –19.6) –25.3 (–29.1 to –21.5) 
P-value vs comparator <0.0001 <0.0001 <0.0001 <0.0001 
HDL-C 6.6 (0.6) –1.0 (0.8) 4.1 (0.4) –0.4 (0.5) 8.1 (0.7) 0.8 (0.8) 7.2 (1.3) 5.3 (1.3) 
LS mean difference vs 
comparator (95% CI) 
7.6 (5.6 to 9.6) 4.5 (3.3 to 5.8) 7.4 (5.3 to 9.4) 1.9 (–1.7 to 5.6) 
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P-value vs comparator <0.0001 <0.0001 <0.0001 0.3059 
Fasting TG (combined 
estimate for adjusted 
mean [SE] % change) 
–8.9 (1.1) 1.4 (1.5) –15.3 (0.8) 1.7 (1.1) –13.0 (1.2) –11.2 (1.5) –10.3 (2.2) –6.0 (2.3) 
Combined estimate for 
adjusted mean 
difference vs 
comparator (95% CI) 
–10.3 (–14.0 to –6.6) –17.0 (–19.7 to –14.3) –1.7 (–5.4 to 2.0) –4.3 (–10.6 to 2.0) 
P-value <0.0001 <0.0001 0.3556 0.1827 
Apo, apolipoprotein; CI, confidence interval; ITT, intent-to-treat; LDL-C, low-density lipoprotein cholesterol; LS, least squares; non-HDL-C, non-high-density lipoprotein 
cholesterol; Q2W, every 2 weeks; SE, standard error; TG, triglyceride. 
Data in patients receiving background statin therapy (pools 1 to 3) have been reported previously   
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Table S3. Safety analysis (pool of 10 Phase 3 trials*) 










Patients with any TEAE 1851 (79.9) 954 (81.3) 657 (76.0) 457 (73.9) 
Patients with any serious 
TEAE 
385 (16.6) 202 (17.2) 147 (17.0) 86 (13.9) 
Patients with any TEAE 
leading to death 
16 (0.7) 13 (1.1) 6 (0.7) 9 (1.5) 
Patients with any TEAE 
leading to permanent 
treatment discontinuation 
144 (6.2) 67 (5.7) 84 (9.7) 66 (10.7) 
TEAE occurring in ≥5% of patients in any pool  
Nasopharyngitis 291 (12.6) 142 (12.1) 52 (6.0) 41 (6.6) 
Upper respiratory tract 
infection 
162 (7.0) 94 (8.0) 62 (7.2) 40 (6.5) 
Myalgia 111 (4.8) 46 (3.9) 62 (7.2) 48 (7.8) 
Injection site reaction 167 (7.2) 62 (5.3) 25 (2.9) 13 (2.1) 
Arthralgia 118 (5.1) 76 (6.5) 42 (4.9) 26 (4.2) 
Accidental overdose 30 (1.3) 17 (1.4) 54 (6.3) 24 (3.9) 
Influenza 147 (6.3) 63 (5.4) 37 (4.3) 23 (3.7) 
Back pain 123 (5.3) 70 (6.0) 33 (3.8) 26 (4.2) 
Headache 119 (5.1) 64 (5.5) 43 (5.0) 24 (3.9) 
Urinary tract infection 128 (5.5) 65 (5.5) 21 (2.4) 25 (4.0) 
Diarrhea 123 (5.3) 57 (4.9) 30 (3.5) 21 (3.4) 
*Placebo-controlled studies include COMBO I, FH I, FH II, LONG TERM, HIGH FH; ezetimibe-controlled studies 
include COMBO II, OPTIONS I, OPTIONS II, ALTERNATIVE, MONO.  
TEAE, treatment-emergent adverse event. 
Adapted with permission from Gaudet et al.2  
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(B) ApoB 
 
The percent values represent the percent change from baseline at each time point. 
*P<0.0001 versus control group. 
ApoB, apolipoproteinB; ITT, intention-to-treat; LS, least squares; non-HDL-C, high-density lipoprotein cholesterol; 
Q2W, every 2 weeks; SE, standard error. 
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Figure S2. Percent of patients achieving non-HDL-C levels of <100 mg/dL 
during the studies, overall and by cardiovascular risk (ITT population) 
(A) All patients (regardless of cardiovascular risk) 
 
(B) Patients with very-high cardiovascular risk 
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(C) Patients with high cardiovascular risk  
 
*P<0.0001 versus control group at all time points in all study pools and patient categories, except for pool 3 and 
pool 4 of the ‘high cardiovascular risk’ category where †P=0.0050, ‡P=0.0015, §P=0.0187, and ‖P=0.0249. 
ITT, intention-to-treat; non-HDL-C, high-density lipoprotein cholesterol; Q2W, every 2 weeks. 
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Figure S3. Percent of patients achieving non-HDL-C levels of <130 mg/dL 
during the studies, overall and by cardiovascular risk (ITT population) 
(A) All patients (regardless of cardiovascular risk) 
 
(B) Patients with very-high cardiovascular risk 
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(C) Patients with high cardiovascular risk  
 
*P<0.0001 versus control group at all time points in all study pools and patients categories, except for pool 3 of 
the “all patients” category where †P=0.0002 and pool 4 of the ‘high cardiovascular risk’ category where 
‡P=0.0063 and §P=0.0058. 
ITT, intention-to-treat, non-HDL-C, non-high-density lipoprotein cholesterol; Q2W, every 2 weeks. 
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Figure S4. Percent of patients achieving apoB levels <80 mg/dL during the 
studies (ITT population) 
 
*P<0.0001 versus control group at all time points and in all study pools. 
ApoB, apolipoproteinB; ITT, intention-to-treat; Q2W, every 2 weeks. 
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